Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
WVE
WVE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
WVE News
Latest Wall Street Rating Updates
Feb 05 2026
CNBC
Wave Life Sciences Regains Full Rights to WVE-006 from GSK
Feb 02 2026
Benzinga
Wave Life Sciences Regains AATD Asset WVE-006 from GSK
Feb 02 2026
seekingalpha
Wave Life Sciences Advances WVE-006 Therapeutic Program
Feb 02 2026
Newsfilter
Eli Lilly and Novo Nordisk Drive Diversification in Obesity Drug Market
Jan 23 2026
CNBC
Wave Life Sciences (WVE) Director Exercises 42,000 Options, Sells for $630,000
Jan 14 2026
Fool
Wave Life Sciences Director Adrian Rawcliffe Sells 42,000 Shares for ~$630,000
Jan 14 2026
NASDAQ.COM
Anticipate a Hectic Year for Obesity Medications with New Pills Launching
Jan 12 2026
Barron's
Wave Life Sciences to Initiate WVE-007 Trials in 2026 with $602 Million Cash Reserves
Jan 12 2026
Globenewswire
Arrowhead Drug Enhances Eli Lilly's Zepbound Weight Loss Results in Initial Trial
Jan 06 2026
Barron's
IHE ETF Shows 9.94% Upside Potential Based on Analyst Targets
Jan 05 2026
NASDAQ.COM
Insights on On-Device AI and the 'Girlfriend Index': Investment Ideas from the Research Firm That Predicted 2025's Trends
Dec 18 2025
MarketWatch
WVE Surpasses Average Analyst Expectations
Dec 10 2025
NASDAQ.COM
Wave Life Sciences Prices $350 Million Public Offering of Shares and Warrants
Dec 10 2025
Globenewswire
Wave Life Sciences Prices Public Offering at $350 Million
Dec 10 2025
Newsfilter
What’s Happening with Wave Life Sciences Stock on Tuesday?
Dec 09 2025
Benzinga
Show More News
